| abstract |
Provided is a cancer treatment method based on a novel mechanism of suppressing proliferation by depleting cysteine for cancer requiring cysteine. A cancer patient who expresses cystathionine γ-lyase in tissue and / or body fluid and / or generates hydrogen sulfide is determined to be a patient who is responsive to cysteine depletion therapy. To select cancer patients who are responsive to cysteine depletion therapy. A therapeutic agent for cancer overexpressing cystathionine γ-lyase, comprising a cystathionine γ-lyase inhibitor and an xCT inhibitor. In addition to the said therapeutic agent, the therapeutic agent characterized by containing the platinum formulation, irinotecan, or SN38 administered simultaneously or separately. [Selection figure] None |